Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi SyndromeGlobeNewsWire • 03/03/22
Tonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi MiceGlobeNewsWire • 02/28/22
Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2GlobeNewsWire • 01/11/22
Tonix Pharma, Kansas University Join Forces To Work On Next-Gen mRNA-Based COVID-19 VaccineBenzinga • 01/04/22
Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell ImmunityGlobeNewsWire • 12/14/21
Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal CancersGlobeNewsWire • 12/13/21
Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic MigraineursGlobeNewsWire • 11/23/21
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI InsightGlobeNewsWire • 11/22/21
Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021GlobeNewsWire • 11/09/21
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021GlobeNewsWire • 11/08/21
Tonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 11/08/21